Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 796 of 6351
-
New hope for kids with Crohn's: risankizumab trial launches
Disease control Recruiting nowCrohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately t…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a meal kit delivery fight depression?
Disease control CompletedThis study experimentally investigates 1) whether ultra processed food (UPF) intake contributes to depression by increasing low mood and poor sleep due to blood glucose fluctuations (which then increases the desire to consume more UPFs) and 2) to investigate the effectiveness of …
Sponsor: University of Michigan • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThe goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a r…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a PET-MRI tracer reveal where CAR-T cells go in myeloma?
Disease control OngoingThis clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Phase 1 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Breakthrough stent aims to fix Hard-to-Treat aortic aneurysms
Disease control Recruiting nowThe Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment…
Sponsor: Cook Research Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat neuroendocrine tumors
Disease control Recruiting nowAn open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
Phase 1/2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New shot during back surgery may boost spine healing in disc disease patients
Disease control Stopped earlyThe primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.
Phase 3 • Sponsor: Angitia Biopharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for kids with rare brain disease: drug targets toxic buildup
Disease control OngoingThis is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 month…
Phase 1/2 • Sponsor: Denali Therapeutics Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take on tough leukemia
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for chronic hives sufferers: drug targets root cause
Disease control OngoingThis is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could a 6-Month drug cocktail beat 9 months for brain TB?
Disease control Recruiting nowThe purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC) treatment for tuberculosis meningitis (TBM).
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Genetic risk + drug combo may halt silent heart disease
Disease control OngoingThe goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary ar…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo aims to stall advanced lung cancer
Disease control OngoingThis is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Phase 2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a new drug combo shrink Hard-to-Treat tumors?
Disease control CompletedThis is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors. The Recommended dose for phase II trial (RP2D) will be determined based …
Phase 1/2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New transplant method aims to cut dangerous immune reaction in half-matched donors
Disease control OngoingPatients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study that will test the safety and…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo aims to control Hard-to-Treat skin lymphoma
Disease control Recruiting nowThis is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be ad…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for Hard-to-Treat lung cancer: which combo works best?
Disease control OngoingThis is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency of atezolizuma…
Phase 4 • Sponsor: Nikolaj Frost MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Smart scans and DNA tests guide lymphoma treatment
Disease control Recruiting nowA prospective, open-abel, phase 2 clinical study to investigate whether interim Positron Emission Tomography (PET) and Epstein-Barr virus (EBV) DNA-directed therapy can improve the prognosis of localized nasal extranodal NK/T cell lymphoma (ENKTL) patients.
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
AI reads brain scans to predict tumor survival before surgery
Knowledge-focused Recruiting nowThis study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a new vaccine shield older kids and adults from three deadly infections?
Prevention CompletedPertussis is an acute respiratory infectious disease caused by Bordetella pertussis, diphtheria is an acute upper respiratory infectious disease caused by Gram-positive Corynebacterium diphtheriae, and tetanus is a highly fatal disease caused by Clostridium tetani infection. Curr…
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC